🇺🇸 FDA

Company profile · Sponsor

Vita

Vita (Europe) Limited

E67B0E6 · EMA pharma GB
Pipeline
5
Drugs
0
Patents
0

Quick answer

Vita (E67B0E6) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 5 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E67B0E6
Exchange EMA
Company type pharma
Headquarters GB

Pipeline (5)

Search pipeline →

  1. SODIO CLORURO 0,9% BAXTER Soluzione per infusione, KETAMINA MOLTENI 50 mg/ml soluzione iniettabile

    Vita

    Major Depressive Disorder (MDD)

    phase 3 small molecule active

    1 trial

  2. SODIO CLORURO 0,9% BAXTER Soluzione per infusione, KETAMINA MOLTENI 50 mg/ml soluzione iniettabile

    Vita

    Major Depressive Disorder (MDD)

    phase 3 small molecule active

    1 trial

  3. -

    Vita

    Primary or advanced breast cancer LumA or ER+ Lobular subtypes.

    phase 2 small molecule active

    1 trial

  4. CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMETREXED, LIBTAYO 350 mg concentrate for solution for infusion.

    Vita

    non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  5. Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer

    Vita

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

Frequently asked questions

What is Vita?

Vita (E67B0E6) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 5 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Vita sponsor?

We track 5 ClinicalTrials.gov-linked programs for Vita, including SODIO CLORURO 0,9% BAXTER Soluzione per infusione, KETAMINA MOLTENI 50 mg/ml soluzione iniettabile and 4 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Vita company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.